Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates

Applied Biopharmaceutics and Pharmacokinetics.

Annals of Internal Medicine · 1981 · 1.2K citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

T. Annie T. Fong, Laura K. Shawver, Li Sun et al. · PubMed · 1999 · 1K citations

Medicine, Oncology, Pharmacology +16

Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis.

Raymond M. Shaheen, Darren W. Davis, Wenbiao Liu et al. · PubMed · 1999 · 337 citations

Medicine, Oncology, Pharmacology +17

Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors

Bart C. Kuenen · Journal of Clinical Oncology · 2002 · 252 citations

Pharmacy, Oncology, Pharmacology +17

Vascular Endothelial Growth Factor in Human Colon Cancer: Biology and Therapeutic Implications

Lee M. Ellis, Yutaka Takahashi, Wenbiao Liu et al. · The Oncologist · 2000 · 196 citations · Full text

Medicine, Oncology, Pharmacology +17